Valenciennes

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending
  2024-516052-17-01 10 Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
• Bosentan in the treatment of Giant Cell Arteritis Pending
  2024-517030-17-00 4 Newly diagnosed or relapsing Giant-cell arteritis
• SPironolactONe for the maintenance of Sinus Rhythm in hypertensive patients with atrial fibrillation and preserved left ventricular ejection … Pending
  2024-518146-25-00 5 patients with atrial fibrillation and preserved left ventricular eject
• Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractli … Pending
  2024-518251-31-00 5 patients hospitalized for a septic shock with hypercontractlity
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending
  2025-521331-36-00 10 Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
• EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management … Pending
  2025-524697-42-00 5 Pleural infections
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Impact of prescribing nonsteroidal anti-inflammatory drugs in pleurodesis surgery after pneumothorax: a prospective randomized controlled do … Recruiting
  2024-511226-32-00 6 2025-05-07 pleurodesis surgery for cure of pneumothorax
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting
  2024-514135-17-00 5 2024-11-28 Immunoglobulin A Nephropathy
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement Recruiting
  2024-519620-24-01 5 2026-06-01 ANCA-associated vasculitis
• PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC) Recruiting
  2025-522109-39-00 5 2026-05-22 Alcoholic hepatitis
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious … Recruiting
  2023-508930-33-00 4 2026-01-30 Non-infectious active cryoglobulinemia vasculitis who are either refra
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro … Recruiting
  2022-501557-36-00 4 2025-12-19 PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
• Therapeutic effect of Hydroxychloroquine on IgA Nephropathy course - QUIgAN Study Recruiting
  2024-512653-25-00 5 2025-06-26 IgA nephropathy
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting
  2024-519219-32-00 5 2025-06-23 Heart Failure With Reduced Ejection Fraction

Showing 1–24 of 97 trials